Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 14/20 | 0.39 |
| ▸ | PAK4 | O96013 | 4/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1885661 | 0.91 | PAK4 (0.35) | IGF1RNTRK1PAK4CDK2NTRK3 | |
| SCHEMBL1371462 | 0.91 | IGF1R (0.45) | IGF1RNTRK1CDK2CCNA2CCNA1 | |
| SCHEMBL1372774 | 0.90 | IGF1R (0.47) | IGF1RNTRK1PAK4CDK2CDK1 | |
| SCHEMBL1373065 | 0.90 | IGF1R (0.44) | IGF1RNTRK1PAK4CDK2CDK1 | |
| SCHEMBL1374090 | 0.88 | IGF1R (0.44) | IGF1RNTRK1PAK4CDK2CDK1 | |
| SCHEMBL1373125 | 0.88 | IGF1R (0.47) | IGF1RNTRK1PAK4CDK2CDK1 | |
| SCHEMBL1371526 | 0.87 | IGF1R (0.48) | IGF1RNTRK1PAK4CDK2CDK1 | |
| SCHEMBL1372310 | 0.86 | IGF1R (0.46) | IGF1RNTRK1PAK4CDK2CDK1 | |
| SCHEMBL1886688 | 0.86 | IGF1R (0.46) | IGF1RPAK4CDK2CCNA2CCNA1 | |
| SCHEMBL1370366 | 0.85 | IGF1R (0.48) | IGF1RNTRK1CDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288088-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.I. (IT) | 2011-11-24 | — | — | US | disclosed |
| US-7968583-B2 | Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288088-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K5, MAP3K19, MAP3K3 | IGF1R 737/4885NTRK1 1363/4885PAK4 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.